ProfileGDS5678 / 1454963_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 81% 82% 81% 80% 81% 76% 76% 79% 81% 81% 83% 80% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5897680
GSM967853U87-EV human glioblastoma xenograft - Control 25.8974781
GSM967854U87-EV human glioblastoma xenograft - Control 35.9221882
GSM967855U87-EV human glioblastoma xenograft - Control 45.9666581
GSM967856U87-EV human glioblastoma xenograft - Control 55.7517980
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5475481
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9489676
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1298476
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5563379
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8704281
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8101881
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1490783
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.668980
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0767883